Pfizer Shot Offers Partial Omicron Shield in Study: Virus Update

Omicron’s ability to evade vaccine and infection-induced immunity is “robust but not complete,” researchers in South Africa said. The data come from the first reported experiments gauging the effectiveness of Covid-19 vaccines against the worrisome new strain.

A vaccine from GlaxoSmithKline Plc and Canada’s Medicago Inc. demonstrated 71% efficacy against multiple variants of Covid. In a separate study, Glaxo said its antibody treatment was effective against omicron and would stand up to all mutations in the spike protein of the virus.